Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3258MR)

This product GTTS-WQ3258MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3258MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5286MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ1825MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ11505MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ3755MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ3302MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ12922MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ606MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ3082MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW